SIGGILLINO, ANNAMARIA
 Distribuzione geografica
Continente #
NA - Nord America 339
EU - Europa 265
AS - Asia 83
Totale 687
Nazione #
US - Stati Uniti d'America 338
IE - Irlanda 110
IT - Italia 55
CN - Cina 29
HK - Hong Kong 24
SE - Svezia 22
SG - Singapore 22
DE - Germania 19
RO - Romania 12
RU - Federazione Russa 12
FR - Francia 11
FI - Finlandia 8
KR - Corea 6
UA - Ucraina 6
CH - Svizzera 5
CZ - Repubblica Ceca 2
GB - Regno Unito 2
IN - India 1
MX - Messico 1
PH - Filippine 1
RS - Serbia 1
Totale 687
Città #
Dublin 110
Chandler 96
San Mateo 33
Hong Kong 24
Medford 17
Princeton 17
Altamura 16
Andover 15
Lawrence 14
Singapore 13
Bucharest 12
Perugia 12
Wilmington 10
Boardman 8
San Paolo di Civitate 6
Seoul 6
Ann Arbor 5
Beijing 5
Redmond 5
Houston 3
Lausanne 3
Moscow 3
Norwalk 3
Nürnberg 3
Rome 3
Saint Petersburg 3
Costa Mesa 2
Kansas City 2
Nanjing 2
Angeles 1
Asso 1
Changsha 1
Chaoyang 1
Fairfield 1
Frankfurt Am Main 1
Granarolo dell'Emilia e Viadagola 1
Guangzhou 1
Henderson 1
Los Angeles 1
Marsciano 1
Nagold 1
Padova 1
Redwood City 1
Tappahannock 1
Trevi 1
Totale 467
Nome #
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: A combined methodology of gene expression profiling and computational gene network analysis 72
KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts) 54
Pathway Activation Mapping of Kras Wild Type and Mutated Adenocarcinomas of the Lung: New Implications For Patient Stratification For Map Kinase Pathway Inhibition 53
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations 49
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 48
Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors 46
Modified gene expression of alveolar-capillar membrane, extracellular matrix and membrane proteins after induction chemotherapy for Non-Small Cell Lung Cancer 46
Variations in gene expression of lung macromolecules after induction chemotherapy for lung cancer 46
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 45
Liquid Biopsy in early Breast Cancer: A preliminary Report 43
Prognostic implications of epidermal growth factor receptor, KRAS and BRAF gene mutations in resected non-small cell lung cancer patients 39
Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study 39
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 37
Role of Expression Levels of Fabp3, H19, Tfpi2, Ark1b1 Cyp3a5, Scgb3a2 Genes In Adenocarcinoma Stage I Patients. 36
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype 28
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 25
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 24
Totale 730
Categoria #
all - tutte 3.250
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.250


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202030 1 7 2 1 0 3 0 5 1 8 2 0
2020/202157 1 2 8 0 26 4 0 1 7 3 4 1
2021/2022135 1 22 2 6 2 0 0 50 0 4 20 28
2022/2023325 17 58 8 22 28 21 0 13 141 0 16 1
2023/2024104 8 10 4 8 0 2 24 0 0 3 26 19
2024/20257 7 0 0 0 0 0 0 0 0 0 0 0
Totale 730